Day 1 - Monday, 23 March 2015
Meeting category
Date(s)
23 Mar 2015 - 24 Mar 2015
Program Language
English
Location
Amsterdam,
Netherlands
Meeting type
Live Meeting
Organizer
International Workshop on Dose Optimization Strategies for Targeted Drugs – Focus on Oncolytics 2015
Related Enduring Materials
Enduring Materials
Session 1: How to select the right drug and the right dose for the individual patient -
Pharmacology as a tool to dose individualize cancer therapy
Early biomarkers as a tool to dose individualize cancer therapy
Timothy Yap, MBBS, PhD, FRCP
University of Texas MD Anderson Cancer Center, USA
Session 2: Approaches to dose individualize/optimize cancer therapeutics -
Obstacles to use dose optimization in an early stage of cancer drug development
A survey of new oncology drug approvals in the United States from 2010 to 2013 – Development paradigms, exposure-response, and the elusiveness of the optimal dose
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer
G. Bjarnason
O_2
Toxicity-adjusted dose (TAD) of sunitinib gives low intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer (mRCC)
Individualized pharmacokinetically-guided dosing of pazopanib: A feasibility study in cancer patients
S. Bins
O_4
Session 3: Dose individualization is commonly and successfully used in other diseases - what can we learn -
Dose Individualization in HIV Therapy
Is cancer different? The first steps to dose individualize and optimize anticancer therapy
Session 4: Abstract driven presentations -
Optimal TDM and pharmacodynamics of mitotane in adrenocortical cancer in children and adults
Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring - The TADE Study.
First intra-patient comparison of antidepressant use among tamoxifen patients
L. Binkhorst
O_7
Everolimus exposure strongly related to dose reductions and mucositis: results of a phase II study in patients with thyroid cancer
Session 5: Mini-orals -
Marker of bevacizumab efficacy: Which place for the pharmacokinetics?
Tyrosine Kinase Inhibitor (TKI) new oncology drug approvals in the United States from 2010 to 2013- A case of turning a blind eye to the optimal dose at the MTD?
Distinguishing safety response of a chemo–radium-223 combination using a model-based analysis of an individual cross-over design
A. Solms
M_15
Microdosing as a pharmacokinetic assessment tool to optimize dosing in children
Dried blood spot sampling for therapeutic drug monitoring of pazopanib.
Polymorphisms of nr1i2 and nr1i3 affect sorafenib and imatinib in vitro activity
Measurement of tumor kinase inhibitor concentrations using PET imaging in patients with advanced solid malignancies
L. Mammatas
M_19
Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions
Day 2 - Tuesday, 24 March 2015
Session 6: Modeling as a tool to individualize the dose and to accelerate drug approval -
Modeling as a tool to individualize the dose and to accelerate drug approval
The use of PK/PD modeling early in drug development and for dose individualizing approaches
Abstract driven presentations: Modeling and simulation approaches in oncology & drug interaction studies -
PKPD modeling of individual lesion maximal standardized uptake value in gastrointestinal stromal tumor (GIST) patients treated with sunitinib
E. Schindler
O_9
Population PKPD modeling of abexinostat-induced thrombocytopenia in phase I and application for the determination of the dose/toxicity relationship
A pre-clinical PKPD framework for biomarker led decision making for prioritising dose and schedules for anti-cancer agents to test in the clinic
Mixed-effect modeling frameworks to optimize treatment of low-grade glioma patients, on population and individual levels
P. Mazzocco
O_12
Closing Session -
Incorporation of dose individualizing approaches in the treatment of cancer – can we learn from the successes in ALL. How will this apply for solid tumors?
Jan Schellens, MD, PhD
Utrecht University, the Netherlands
Panel Discussion - Dose optimization strategies: changes, threats and challenges in the next 20 years.
Overview
Dear Colleagues,
The first edition of the International Workshop on Dose Optimization Strategies for Targeted Drugs - Focus on Oncolytics, held on 23 - 24 March 2015 in Amsterdam, the Netherlands, was a great success.
We would like to thank all invited speakers and participants for their contribution to this workshop.
Yours sincerely,
The Organizing Committee
